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a b s t r a c t
The lower incidence rate of transitional cell carcinoma of the urinary bladder in blacks than
in whites may be due to racial differences in the catalytic activity of enzymes that
metabolize carcinogenic arylamines in tobacco smoke. To examine this, we compared
cytochrome P4501A2 (CYP1A2) and N-acetyltransferase-2 activities (NAT2) in black and
white smokers using urinary caffeine metabolites as a probe for enzyme activity in a
community-based study of 165 black and 183 white cigarette smokers. The paraxanthine
(1,7-dimethylxanthine, 17X)/caffeine (trimethylxanthine, 137X) ratio or [17X + 1,7-dimethy-
luric acid (17U)]/137X ratio was used as an indicator of CYP1A2 activity. The 5-acetyl-amino-
6-formylamino-3-methyluracil (AFMU)/1-methylxanthine (1X) ratio indicated NAT2 activ-
ity. The odds ratio for the slow NAT2 phenotype associated with black race was 0.4; 95%
confidence intervals 0.2–0.7. The putative combined low risk phenotype (slow CYP1A2/rapid
NAT2) was more common in blacks than in whites (25% vs. 15%, P < 0.02). There were no
significant racial differences in slow and rapid CYP1A2 phenotypes, and in the combined
slowNAT2/rapid CYP1A2 phenotype. Age, education, cigarette smoking amount, bodymass
index, GSTM1 and GSTM3 genotypes were unrelated to CYP1A2 and NAT2 activity. Intake of
cruciferous vegetables (primarily broccoli), red meat, carrots, grapefruit and onions pre-
dicted CYP1A2 activity either for all subjects or in race-specific analyses. Carrot and grape-
fruit consumption was related to NAT2 activity. Collectively, these results indicated that
phenotypic differences in NAT2 alone or in combination with CYP1A2 might help explain
the higher incidence rates of transitional cell bladder cancer in whites.
# 2008 Elsevier Inc. All rights reserved.
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Bladder cancer is the fourthmost commonly diagnosed cancer
in men and eighth most common in women in the United
States. The incidence rates of transitional cell carcinoma,
which account for the majority of bladder tumors, are
approximately twice as high in white men vs. black men
and 1.5 times higher in white women than in black women [1].
Squamous cell carcinoma of the bladder is rare but higher in
blacks than inwhites [2]. Tobacco smoke contains arylamines,
which are a known class of bladder carcinogens and thought
to be the likely causative agent responsible for the increased
risk of bladder cancer in cigarette smokers [3,4]. The major
route for arylamine activation to reactive electrophiles
involves N-hydroxylation by cytochrome P4501A2 (CYP1A2)
[5]. The detoxification pathway occurs via N-acetylation by N-
acetyltransferase-2 (NAT2) [6]. Differences in the activity of
these enzymatic pathways may affect the risk for bladder
cancer as the slow acetylation phenotype and polymorphisms
in NAT2 genes have been linked with increased levels of 4-
aminobiphenyl (4-ABP)–hemoglobin adducts in smokers and
with increased risk for bladder cancer [7,8].
The urinary ratios of caffeine metabolites (Fig. 1) are
commonly used as a probe for the in vivo phenotyping of
CYP1A2 [5]. Approximately 95% of the primary systematic
clearance of caffeine has been attributed to CYP1A2 activity
[9]. Twin studies indicate that most of the wide variation in
CYP1A2 activity is determined by genetic factors [10]. However
among the >25 single nucleotide polymorphisms in CYP1A2
that have been identified (www.imm.ki.se/CYPalleles), few
have been associated with altered function. The CYP1A2*1C
and CYP1A2*1F polymorphisms have been associated with
decreased enzyme inducibility in smokers [11,12]. CYP1A2
activity is also induced or affected by cigarette smoking, diet,
and environmental factors [13–15]. Some data indicate that
activity levels may vary by race or ethnicity. In children, mean
urinary caffeine metabolite ratios were higher in whites thanFig. 1 – Simplified scheme for caffeine metabolism. CYP1A2
catalyzes the 3-demethylation of caffeine (137-X) to
paraxanthine (PX; 1,7,DMU) and NAT2 catalyzes the
acetylation of PX metabolites to 5-acetyl-amino-6-
formylamino-3-methyluracil (AFMU). The ‘‘?’’ refers to a
postulated intermediate. This figure was adapted from
Grant et al. [19].in blacks [16]. In contrast theophylline clearancewas higher in
blacks than in whites and latinos [17], and propranolol 4-
hydroxylase activity in liver microsomal specimens was
higher in samples obtained from black surgical patients than
from white patients [18].
Measurement of caffeine metabolites has also been used
for the assessment of NAT2 activity (acetylation phenotype),
as the formation of 5-acetylamino-6-formylamino-3-methy-
luracil (AFMU) from caffeine is principally catalyzed by the
non-inducible NAT2 (Fig. 1) [19,20]. Genetic polymorphisms in
the NAT2 gene are predictive of bladder cancer [21]. They are
also correlatedwith theNAT2 activity, explaining about half of
the variance in the distribution of the AFMU/1X phenotype
[22–24]. However there is little data on racial differences in the
NAT2 phenotype. The slow isoniazid acetylation phenotype
was more common in black American and African tubercu-
losis patients than in white patients [25,26]. Other data
indicate similar isoniazid acetylation phenotype prevalences
between white and black Americans [27,28]. The slow
sulphamethazine acetylation phenotype was more prevalent
in Nigerian than in various Caucasian subjects [29–35]. The
slow NAT2 genotype was reported to be more common in
whites than in black South Africans [36].
Utilizing the measurement of urinary caffeine metabolites
to assess metabolic phenotype for CYP1A2 activation and
NAT2 detoxification pathways [37–39], we sought to determine
if racial differences in the biochemical activation or detox-
ification of arylamines might contribute to the higher
incidence rates of bladder cancer in whites than in blacks.
Thus, the current study compares the CYP1A2, NAT2 and their
combinedphenotypes in a large group of black andwhite adult
smokers. Since polymorphisms in glutathione transferases
(GST), including GSTM1-null, together with slow acetylation
phenotype have been linked with increased risk of bladder
cancer [40–43] and GSTM1 null genotype was associated with
enhanced 4-ABP hemoglobin adducts [44], we also examined
the effects of GSTM polymorphisms on CYP1A2 and NAT2
activity.2. Materials and methods
2.1. Materials
Caffeine (137X) and its metabolites 1,7-dimethylxanthine
(17X), 1-methylxanthine (1X), 1,7-dimethyluric acid (17U),
and 1-methyluric acid (1U) were obtained from Sigma
Chemical Co. (St. Louis, MO). 5-Acetylamino-6-formylamino-
3-methyluracil was obtained from Dr. B.K. Tang at the
University of Toronto. All other reagents were obtained from
SigmaChemical Co. (St. Louis,MO) unless otherwise indicated.
2.2. Subjects and study design
Therewere 348 (165 non-Hispanic black and 183white) current
cigarette smokers who participated in the caffeine testing, as
part of a larger study of over 600 subjects recruited for studies
of smoking biomarkers. The subjects were recruited from
Mount Vernon, Yonkers and other areas in southeastern
Westchester County, NY [45,46]. Smokeless tobacco, pipe and
b i o c h em i c a l p h a rma c o l o g y 7 6 ( 2 0 0 8 ) 9 2 9 – 9 3 7 931cigar users were ineligible to participate. Mt. Vernon is a
racially diverse middle-income community of 65,000 resi-
dents. The recruitment methods included fliers, public
lectures, newspapers advertisements, and word of mouth.
All subjects signed a written informed consent approved by
the Institutional Review Board of the Institute for Cancer
Prevention, and refrained from caffeine intake for 24 h before
sample collection. We collected an early morning urine
sample from each subject, and at approximately 9 a.m. the
subjects were provided an 8-oz. cup of hot water containing 2
tablespoons of instant coffee. The beverage was consumed in
its entirety within 10 min. Additional urine specimens were
collected 3 and 4 h after the morning sample and were
immediately frozen and stored at 20 8C.
2.3. Questionnaire
We interviewed each subject using a structured questionnaire
that contained items on demographics and lifestyle factors
such as number of cigarettes smoked per day (cpd). Usual food
intake was assessed using a validated food frequency
questionnaire [47].
2.4. Determination of CYP1A2 and NAT2 phenotypes by
caffeine metabolites
In the 4 h urine samples, we measured caffeine and its
metabolites 17X, 1X, 17U, 1U, and AFMU [13,35–37]. The frozen
urine sampleswere thawed at room temperature and adjusted
to pH 3.5 with HCl. Aliquots (200 ml) were saturated with
120 mg of ammonium sulfate. After addition of 200 ml of
internal standard (120 mg/ml 4-acetamidophenol in chloro-
form) 6 ml of chloroform:isopropanol (19:1) was added. After
centrifugation at 3000  g for 5 min, about 5.5 ml of the organic
phase was removed and evaporated to dryness at 42 8C under
nitrogen. Samples were resuspended in 1 ml of 0.05% acetic
acid and filtered through a 0.22-mm syringe filter.
High performance liquid chromatography (HPLC) was
performed by separating the metabolites using a reversed-
phase 4.6 mm  250 mmcolumn (Inertsil ODS-3, GL Sciences,
Inc., Torrance, CA) and eluted with mobile phases A (0.045%
acetic acid and 9% methanol) and B (100% methanol) using a
gradient profile starting at 10% B to 16.5 min, increasing to
20% B from 16.5 to 19.8 min and continuing at 20% B for
27 min. A 5 min washout period with 100% B and a 15 min re-
equilibration period with 10% B was used between samples.
The standards included AFMU, 1U, 1X, 17U, 17X, 137X, andTable 1 – Cigarette smoking characteristics in subjects from W
Smoking history n Blacksa
Age started 165 16.7  4.1
Years of smoking 165 17.3  8.1
Cigarettes per day 165 14.2  8.1
Menthol status
Mentholated (%) 138 83.6
Non-mentholated (%) 27 16.4
a Values are mean  S.D.internal standard. Spectral conformation of caffeine meta-
bolite peaks was performed routinely, using a programmable
multiple wavelength detector (Waters 490E, Waters Corp.,
Milford, MA). Using this methodology, recovery of caffeine,
paraxanthine, AFMU and 1-methylxanthine ranged from 91
to 103%.
Caffeine 3-demethylation activity (CYP1A2) was assessed
by determining the ratio (17X + 17U)/137X, as described
previously [20]. Use of this molar ratio was based upon its
high correlation (r = 0.73) with the rate constant for hepatic 3-
demethylation of caffeine in a pharmacokinetic study
(calculated as the ratio of rate constants for the hepatic
conversion of caffeine to paraxanthine and the excretion of
caffeine into urine) [20]. This ratio typically falls into three
phenotypes (slow, intermediate or fast). Both CYP1A2 and
CYP2A6 are involved in the 7-demethylation of 17X with the
later playing the principal role [48]. In addition, the ratio 17X/
137X was also assessed as originally described [49] which
typically yields two phenotype (slow and fast). Since previous
caffeine phenotyping studies measured enzyme activity
either by area ormolar ratios, bothmeasures were calculated
and compared in the present study. The frequency distribu-
tion of (17X + 17U)/137X in our data indicated a trimodal
distribution, with cut points that represented 10% (slow), 54%
(intermediate) and 37% (rapid) of the distribution. The
distribution of 17X/137X was bimodal with a cut point of
1.85 separating slow and rapid phenotypes. The cut pointwas
confirmed by examination of a 17X/137X probit plot. About
75% of subjects were classified as slow activators based on
17X/137X levels.
In 279 subjects (122 blacks and 170 whites), CYP1A2
phenotype was calculated by both peak area andmolar ratios.
The correlation betweenpeak areas andmolar determinations
was 0.99 for (17X + 17U/137X) and 0.96 for (17X/137X). We
therefore report the findings based on peak area ratios since
these values were determined for all subjects.
The ratio of AFMU/1-methylxanthine was calculated to
measure acetylation phenotype (NAT2 activity). The activity
levels were not measured for a few samples because of the
presence of interfering urinary constituents that co-migrate
with caffeine on HPLC in those samples. Subjects were
classified as slow and rapid acetylators based on the
distribution of these values. The variation of the analytical
method was assessed by an analysis of control samples. The
overall variation (CV) for control values (long-term assay CV)
were 7.3, 8.4, 11.4, 9.7 and 12.1% for 137X, 17U, 17X, 1X and
AFMU, respectively.estchester County, NY
n Whitesa P-value
183 16.1  3.8 0.15
184 16.4  10.2 0.35






















































































































































































































































































































































































































































































































































































































































































































































































































b i o c h em i c a l p h a rma c o l o g y 7 6 ( 2 0 0 8 ) 9 2 9 – 9 3 79322.5. Determination of urinary cotinine and creatinine
ELISA (OraSure Technologies, Inc., Bethlehem, PA) was
performed to quantify levels of urinary cotinine in the
morning void sample. A Vitros Ektachem 500 clinical chem-
istry analyzer (Ortho Clinical Diagnostics of Johnson &
Johnson, Rochester, NY) was used to measure urinary
creatinine levels in the same sample.
2.6. Determination of GSTM1 and GSTM3 genotypes
The GSTM3 intron 6 polymorphismwas determined in a subset
of 216 subjects by restriction fragment length polymorphism
analysis using exon 6/exon 7 primers (50-CCTCAGTACTTGGAA-
GAGCT-30; 50-CACATGAAAGCCTTCAGGTT-30) and MnlI diges-
tion using methods previously described [50]. The presence
of the GSTM1 null polymorphism was determined using a
3-primer-based PCR assay as previously described [50].
2.7. Statistical analysis
Means, standard deviations, ranges, and frequency distribu-
tions were calculated to summarize the data. We determined
the normality of the distributions using the Kolomogorov–
Smirnov test and visual examination of frequency plots. The
Student’s t-test compared descriptive data and caffeine ratios
between blacks and whites. Pearson correlations were
calculated to determine the association between the peak
AUC and themolar ratio. Pearson correlation coefficients were
calculated between potential predictors of enzyme activity
levels, such as age and smoking amount, and the log-
transformed values of the CYP1A2 and NAT2 ratios. Caffeine
phenotype categories were defined as slow vs. rapid activators
and slow vs. rapid acetylators. The combined phenotypes
were classified as slow NAT2/slow CYP1A2, slow NAT2/rapid
CYP1A2 (the putative highest risk group), rapid NAT2/slow
CYP1A2 (the putative lowest risk group) and rapid NAT2/rapid
CYP1A2. We conducted unconditional logistic regression
analyses to test the association between phenotype category
and race using SAS statistical software (Version 8.2, Cary, NC).
A forward selection method was used for the logistic models
using an entry probability criterion of 0.25. The covariates
included sex, age, education, and smoking amount (e.g. ratio
of urinary cotinine-to-creatinine per dl, or alternatively
smoking amount categorized as 5–9, 10–19, 20–29, 30–39 and
40 cpd). The proportional odds model was fitted for the
trimodal CYP1A2 phenotype by assigning the values into three
ordinal categories (1 = slow, 2 = intermediate and 3 = rapid).
The proportional odds assumption and the fit of the logistic
regression models were tested by the Score and Hosmer–
Lemeshow tests, respectively. Chi-square tests were calcu-
lated to determine proportional differences in combined
CYP1A2/NAT2 phenotypes by race. Sample sizes for these
different analyses varied as data on CYP activity was missing
for 1 subject, data on acetylation activity was missing for 18
subjects, and 19 subjects had amissing value either for CYP or
NAT2.
In exploratory analyses, forward stepwise regression was
conducted to determine the effects of food items on the log-
transformed CYP (17U + 17X/137X) and NAT2 phenotypic
b i o c h em i c a l p h a rma c o l o g y 7 6 ( 2 0 0 8 ) 9 2 9 – 9 3 7 933ratios. The foods included cruciferous vegetables (broccoli,
cabbage), onions, carrots, red meat (beef, pork), cured meats
(ham, hot dog, bacon, sausage), fish, tomatoes/tomato juice,
total fruit/fruit juice consumption, and high fiber breads and
cereals. Except for total fruit consumption, the distribution of
dietary intake was not normally distributed and tended to be
multimodal. Consequently food itemswere grouped into three
frequency categories and assigned the median value of intake
for each group. The model entry criterion was set at a liberal
0.45 P-value. All P-values were two-sided and considered
significant at <0.05.3. Results
The subjects included 82 blackmen, 83 blackwomen, 89 white
men and 94 white women. The mean age was 34.8 in blacks
and 33.2 in whites, and the age of smoking onset and total
years of smoking were similar between blacks and whites
(Table 1). The mean daily cigarette intake was 14.2 in blacks
and 22.3 in whites. More blacks than whites smoked
mentholated cigarettes (83.6% vs. 23.0%, P < 0.01). AFMU/1X
values were determined for 330 subjects.
The correlation coefficients for age, body mass index and
cigarettes per day with CYP1A2 measures in all subjects were
all j0.13j. Similarly, the correlation coefficients for age,
education, BMI and cpdwithNATwerej0.14j. The correlation
coefficients between the GST genotypes and CYP1A2 and
NAT2 phenotypes were j0.09j. In race specific analysis, the
correlation between GSTM1 null genotype and acetylation
phenotype was 0.16 (P < 0.13) in whites, and the correlation
between the GSTM3 genotype and acetylation phenotype was
0.18 (P < 0.09).
Themean values and the ranges for the caffeinemetabolite
ratios are presented in Table 2 by race, sex and phenotype
categories. There were no significant differences in mean
(17X + 17U/137X) values between white and black men. The
mean ratio was 7.7 in black women and 6.0 in white women
(P = 0.07). Themean ratio of 17X/137Xwas similar for black and
white men, and higher in black vs. white women (3.0 vs. 2.1,
P = 0.02). The mean ratio for AFMU/1X was 0.21 in black men
and 0.16 in white men (P = 0.18), and 0.32 in black women and
0.13 in white women (P < 0.01). In rapid acetylators, the values
were 0.51 for blackwomenand 0.25 forwhitewomen (P = 0.02).
The prevalence of the putative high risk GSTM1 null genotype
was substantially greater in whites (45.3%) than in blacksTable 3 – Odds ratio for NAT2 and CYP1A2 phenotypes associ
Race NAT2 (AFMU/1X)a OR 95% CI CYP1A2
(17X/137X)a
Slow Rapid Slow Rapid
Whites 140 (56) 29 (36) 1.0 142 (55) 41 (47)
Blacks 109 (44) 52 (64) 0.4 0.2, 0.7 118 (45) 46 (53)
Abbreviations: OR = odds ratio. CI = confidence intervals, POR = proportio
age, education, sex and urinary cotinine/creatinine. Sample sizes for wh
due to missing values for covariates. The model for (17X + 17U)/137X is u
a Values are number (%).(18.5%). The prevalence of the GSTM3*B homozygous genotype
consisting of a 3-bp deletion in intron 6 of the GSTM3 gene
which has been postulated to increase GSTM3 transcription
[51] and has been linked to decreased risk for certain cancers
[51,52] was greater in blacks (37%) than in whites (1.9%).
The odds ratio for the slow CYP activation (17X/137X)
phenotype associated with black race was 0.74; 95% CI 0.5–1.2
(Table 3). None of the covariates tested were associated with
the activation phenotype. Sex-specific odds ratios were also
not statistically significant. The proportional odds ratio for the
(slow vs. intermediate vs. rapid) CYP1A2 ([17U + 17X]/137X)
activation phenotype associated with black race was 0.8; 95%
CI 0.6–1.2. The proportional odds assumptionwas validated by
Chi-square analysis (P = 0.84).
The mean AFMU/1X ratio was higher in blacks than in
whites (0.27  0.47 vs. 0.14  0.23, P < 0.01; Table 2). More
blacks thanwhiteswere classified as rapid acetylators (64% vs.
36%; P < 0.05, Table 3). The odds ratio for the slow NAT
phenotype associated with black race was 0.4; 95% CI 0.2–0.7
(Table 3). The cotinine-to-creatinine ratio was associated with
slow acetylation (P = 0.09). Using reported cigarettes smoked
per day as an alternativemeasure to cotinine, only smoking2
packs (40 cpd) vs. < 10 cpd was associated with the slow
acetylation phenotype (P = 0.04).
There were significant racial differences in the prevalence
of the combined CYP1A2/NAT2 phenotypes (Table 4). There
were significantly more blacks than whites in the putative
lowest risk category, e.g. slow CYP1A2 (17X/137X)/rapid NAT2
phenotype (24.4% vs. 14.8%, P < 0.02) compared to the other
three combined phenotypes. The sex-specific findings for the
slow CYP1A2 (17X/137X)/rapid NAT2 phenotype were similar
(22.7% vs. 16.8% in men and 27.5% vs. 13.0% in women). There
were no significant racial differences in the proportion of the
putative highest risk phenotype, e.g. the rapid CYP1A2 (17X/
137X)/slow NAT2 group (20.6% vs. 21.9%) compared to the
other three phenotypes combined. Similar results were found
for the combined (17X + 17U/137X) and NAT2 phenotypes
(Table 4).
In stepwise regression analysis examining dietary intake,
cruciferous vegetable and red meat intake were significant
predictors of CYP1A2 activity (Table 5).When stratified by race,
carrot and onion consumption were predictors of CYP1A2
activity while grapefruit consumptionwas inversely related to
CYP1A2 activity. There were no significant dietary predictors
in black subjects. There were no significant dietary predictors
of NAT2 activity, although marginal associations wereated with black race in cigarette smokers
OR 95% CI CYP1A2 (17X + 17U)/137Xa POR 95% CI
Slow Intermediate Rapid
1.0 35 (56) 86 (54) 62 (50) 1.0
0.74 0.5–1.2 28 (44) 73 (46) 63 (50) 0.8 0.6, 1.3
nal odds ratio. Models for AFMU/1X and 17X/137X are adjusted for
ites is one less than that listed in Table 2 for both NAT2 and CYP1A2
nadjusted for confounders.
Table 4 – Combined CYP1A2 and NAT2 phenotypes in
black and white smokers
Phenotype Blacks n (%) Whites n (%) P-value
CYP1A2 (17X/137X)/NAT2
Slow/slow 76 (47.5) 103 (61.0) <0.02
Slow/rapida 39 (24.4) 25 (14.8)
Rapid/slow 33 (20.6) 37 (21.9)
Rapid/rapid 12 (7.5) 4 (2.4)
CYP1A2 [(17X + 17U)/137X]/NAT2
Slow/slow 13 (8.1) 22 (13.0) <0.02
Slow/rapida 14 (8.8) 4 (2.4)
Intermediate/slow 53 (33.1) 64 (37.9)
Intermediate/rapid 18 (11.2) 17 (10.1)
Rapid/slow 43 (26.9) 54 (32.0)
Rapid/rapid 19 (11.9) 8 (4.7)
a Putative ‘low risk’ category.
b i o c h em i c a l p h a rma c o l o g y 7 6 ( 2 0 0 8 ) 9 2 9 – 9 3 7934observed with cruciferous vegetable intake and carrot con-
sumption (Table 5). When stratified by race, there was a
significant associationwith grapefruit consumption inwhites.
There were no significant predictors in blacks.4. Discussion
The phenotypic characterization of CYP1A2 can be subjective,
with as many as 50% of subjects classified as rapid activators.
Butler et al. [20] reported a trimodal distribution (17X + 17U)/
137X in a number of different populations of 12–13% slow, 51–
67% intermediate, and 20–37% rapid. This was similar to our
trimodal distribution (10%, 54% and 37%). The bimodal
distribution of 17X/137X indicated that about 30% of our
subjects were rapid activators, which was similar to findings
reported elsewhere [16].
We found that the slow acetylation phenotype was more
highly prevalent in white than in black study participants
regardless of gender,which is consistentwith previous reports
based on caffeine testing [16,32]. The percent of slow
acetylators in white study subjects in this study was 51%,
slightly higher than that observed (45%) in a pooled genotyping
analysis [53]. Higher AFMU/1X molecular ratio values were
observed in blacks compared to whites (P < 0.01) although this
difference was primarily observed among rapid acetylators. In
addition, 11 of the 12 subjects with the highest acetylation
activity levels were black. Altogether, these results suggest
that N-acetylation activity is greater in blacks compared toTable 5 – Dietary predictors of CYP1A2 and acetylation activit
Dietary item CYP1A2
Partial r P-value
Cruciferous vegetables 0.11 0.01




a Value is for white subjects only.whites. A possible mechanism for these phenotypic differ-
ences may likely involve racial differences in the distribution
of NAT2 genotypes as previous studies indicate a greater
prevalence of NAT2 genotypes associated with rapid acetyla-
tion among blacks compared to whites [54]. In our data, no
associations with the NAT2 phenotype were found with age,
sex, education, BMI, and cigarettes per day. Other investiga-
tions have also found that sociodemographic and lifestyle
factors are unrelated to acetylation levels [24,55–57]. Our data
did show an association between heavy smoking (40 cpd)
and the slow acetylation phenotype, but this finding is
possibly due to residual confounding by race as nearly all
heavy smokers were white study subjects, who had lower
acetylation activity.
There were no differences in mean CYP1A2 activity
between blacks and whites. The caffeine ratios for CYP1A2
were lower in white women than in white men, which is
consistent with previous reports [16,58,59], although no sex
differences were found in a controlled dietary trial [60]. There
were no differences in the mean CYP1A2 caffeine ratios
between black women and black men. However, the putative
low risk combined slow CYP1A2/rapid NAT2 phenotype was
more common in blacks than in whites.
The effects of specific dietary items on CYP1A2 activity
has received little attention. Detecting such associations in a
typical American diet is difficult because of the well known
limitations in dietary recall and the ability to accurately
quantify dietary intake by food frequency questionnaires.
The effect size of any specific dietary item on a biomarker
may also be small, and the frequency of specific food items is
often highly correlated with other foods within food groups.
In addition, multiple comparisons and analysis done in
subgroups increase the likelihood of type I error and
decrease statistical power, respectively. Despite these
limitations, we found that CYP1A2 activity was weakly
correlated with cruciferous vegetable intake. While there is
little data supporting a protective role for vegetable intake
on bladder cancer risk, recent data indicate that broccoli
sprout extracts inhibit bladder cancer development in rats in
a dose-dependent manner [61]. Our findings are consistent
with the finding that brassica (cruciferous) vegetables
increased and apiaceous vegetables decreased CYP1A2
activity relative to a vegetable-free diet in a four-arm
randomized crossover dietary trial [59]. In another study
of nine healthy volunteers, daily intake of 500 g of broccoli
for 10 days increased CYP1A2 activity by 12% compared to a
control group [62]. Our finding for cruciferous vegetablesy in stepwise regression
Acetylation
Model r2 Partial r P-value Model r2
0.034 0.03 0.09 0.02
0.13 0.06
0.04a 0.02
b i o c h em i c a l p h a rma c o l o g y 7 6 ( 2 0 0 8 ) 9 2 9 – 9 3 7 935(primarily broccoli) is also consistent with findings of
frequent consumption associated with increased CYP1A2
activity in a Los Angeles-based study [63] where the effect
was limited to subjects with the GSTM1 null genotype.
However, we found no effect of cruciferous vegetable
consumption when stratifying by GSTM1 genotype. The
mechanism for CYP1A2 induction by cruciferous vegetable
intake is unknown. While isothiocyanates derived from
cruciferous vegetables are potent inducers of numerous
phase II detoxification enzymes through a mechanism
involving enhancement of the redox sensitive transcription
factor Nrf2, there have been no reports of a possible role of
nrf2 in regulating P450 isozymes other than CYP2A5 [64]. In
addition, other laboratory studies demonstrated an inhibi-
tory effect of Isothiocyanates on CYP1A2 activity [65].
In our data, grapefruit consumption inhibited both CYP1A2
and acetylation activity in whites, however, we did not have
information on grapefruit juice intake. This effect on CYP1A2
is consistent with in vitro data [66]. To our knowledge, there
have been no previous reports on grapefruit juice and
acetylation activity, however, in 90 Hawaiians of various
ethnic backgrounds, cruciferous vegetable intake was unre-
lated to acetylation activity [24]. While NAT2 is not thought to
be an inducible enzyme, associations with grapefruit intake
could be facilitated throughpotential effects of grapefruit juice
on the excretion of caffeine metabolites.
GST polymorphisms have been linked with bladder cancer
risk [41–43] and in one study GSTM1 null genotype was linked
with enhanced 4-ABP adduct formation suggesting that it may
contribute to racial variation in 4-ABPmetabolism and bladder
cancer risk [44]. However, other studies found no associations
between GST activity and 4-ABP metabolism [67]. In the
present study, no associations between GSTM1 and GSTM3
genotype and NAT2 or CYP1A2 was observed. Higher pre-
valence of putative higher risk genotypes of both GSTM1 and
GSTM3 inwhites than in blackswere similar to those observed
previously [44,50].
The reasons why whites have higher rates of bladder
cancer are not fully understood, particularly since blacks
have higher rates of other tobacco-related cancers. Over the
past several decades, the smoking prevalence has been lower
in whites, but white smokers are more likely to be heavy
smokers (>1 pack/day) [67]. However while smoking amount
is correlated with Hb adduct levels up to 20 cpd, higher doses
do not increase Hb levels further [68]. Further, blacks prefer
mentholated cigarettes, which have highermachine-smoked
‘‘tar’’ and possibly 4-ABP concentrations than non-mentho-
lated cigarettes. Mixed findings have been reported on
differences in the association between smoking and bladder
cancer risk between whites and blacks [69–71]. The present
finding of racial differences in the prevalence of NAT2
phenotypes alone or in combination with CYP1A2 pheno-
types may help explain these racial differences bladder
cancer risk. The greater prevalence of the slow acetylation
phenotype inwhitesmay be associatedwith decreased 4-ABP
detoxification and, thus, greater susceptibility to cell bladder
cancer development as slow acetylation has been associated
with elevated protein and DNA adduct levels in smokers
[7,72–75], and modest increases the risk for bladder cancer
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